Melanotan II vs Prostamax
A side-by-side research comparison of Melanotan II and Prostamax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Melanotan II | Prostamax |
|---|---|---|
| Full name | Melanotan II (MT-II) | Prostamax (Prostate Peptide Bioregulator) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound | Research compound (peptide bioregulator) |
| Mechanism | Non-selective MCR agonist: MC1R produces tanning, MC3R/MC4R increase sexual arousal, MC4R suppresses appetite. Broader receptor activity than PT-141. | As a signal peptide, it is proposed to regulate gene expression in prostate tissue, supporting normal prostatic function, reducing inflammation-related dysfunction, and maintaining healthy urogenital tissue. |
| Molecular weight | 1,024 Da | ~ (short peptide) |
| Half-life | 2-3 hours | Short (peptide) |
| Bioavailability | High (SubQ) | Oral (encapsulated) or subcutaneous |
| Typical dose | 0.25-1 mg | ~1-2 capsules/day or short injectable courses |
| Frequency | Loading: daily/EOD · then 2x weekly maintenance | Once daily |
| Route | Subcutaneous injection | Oral capsule or subcutaneous |
Melanotan II reported benefits
- Skin tanning
- Enhanced sexual function
- Appetite suppression
- UV protection (melanin)
- Libido enhancement
Prostamax reported benefits
- Prostate tissue support (proposed)
- Male urogenital health
- Anti-inflammatory tissue signaling (proposed)
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.